The EBIACE-1 trial represents a significant advancement in understanding insulin delivery options for type 1 diabetes management. This randomized crossover study of 31 adults compared the InPen smart insulin pen directly against the MiniMed 780G automated insulin delivery system over six-month treatment periods. While both technologies integrate with continuous glucose monitoring, they operate at different automation levels. The smart pen assists with injection-based dosing and bolus calculations, whereas the automated insulin delivery system continuously adjusts insulin based on glucose readings using an algorithm. Study findings revealed that automated insulin delivery produced considerably better average glycemic control, measured by hemoglobin A1C and time in range metrics. However, nearly half of participants achieved near-optimal glycemic control using the smart pen alone. These results highlight an important clinical consideration: while automated systems demonstrate superior average outcomes, individual patient preferences and technological comfort vary significantly. The findings reinforce automated insulin delivery's effectiveness while raising questions about whether maximum automation suits every patient's needs, suggesting that personalized treatment approaches remain essential in type 1 diabetes management.

The American Diabetes Association and European Association for the Study of Diabetes have released updated consensus statements addressing critical gaps in diabetes management. Key updates include guidance on population screening for islet autoantibodies to enable early-stage type 1 diabetes diagnosis, alongside clinical guidelines optimizing the assessment and management of diabetes distress in both type 1 and type 2 diabetes patients, emphasizing person-centered care. Multiple educational initiatives are underway, including a two-day conference in Birmingham covering diabetes, obesity, and associated conditions, webinar series exploring evolving management landscapes in primary care, and Diabetes UK's 15th Pregnancy Conference. Recent research advances include studies examining psychosocial dimensions of diabetes technology use in adults with type 1 diabetes, menstrual cycle effects on glycemic patterns and insulin sensitivity, and a significant trial evaluating IcoSema, a once-weekly combination therapy combining basal insulin icodec and semaglutide. Additionally, new frameworks have been developed for continuous glucose monitoring system performance evaluation, practical guides for insulin optimization, and surveillance data on maternal mortality, collectively strengthening evidence-based diabetes management across diverse populations and care settings.

Call-On-Doc has launched a compounded weight loss medication service designed to address affordability challenges in the booming weight loss injection market. The service offers compounded semaglutide at $190 monthly with free home delivery, significantly undercutting name-brand alternatives like Ozempic, Mounjaro, and Saxenda, which can cost approximately $1,000 per month. The announcement responds to unprecedented demand for weight loss injections fueled by celebrity endorsements, which has created widespread shortages and accessibility issues. Call-On-Doc's streamlined online consultation process takes five to ten minutes, enabling patients to complete medical histories and receive prescriptions within three to five days. The service is available nationwide except in Mississippi, Alabama, South Carolina, and California. This initiative addresses healthcare disparities by democratizing access to prescription weight loss treatments, aligning with Call-On-Doc's stated mission to make high-quality healthcare affordable and accessible to broader populations.

GLP-1 medications represent a significant advancement in weight management and blood sugar control, with semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) among the most commonly prescribed options. The first month of GLP-1 therapy is primarily an adjustment period rather than a time of dramatic results. Patients typically start on a low introductory dose designed for tolerability, with most noticing reduced appetite within one to two weeks as the medication works by mimicking the natural hormone glucagon-like peptide-1, which regulates hunger and blood sugar while slowing gastric emptying. Common side effects during this period include mild nausea and digestive changes, particularly when consuming heavy or large meals. Weight loss in month one is typically modest, as providers intentionally begin with conservative dosing and increase gradually every four weeks to allow the digestive system to adapt. By weeks two and three, clearer changes emerge as patients adjust eating habits toward smaller, protein-forward meals. This gradual approach ensures safety and sustainability, with providers reassessing tolerance at month's end before determining dose escalation. Individual responses vary significantly based on medication type, starting dose, and personal health factors.

Nearly 40 million Americans with diabetes face round-the-clock blood sugar management, which often creates significant psychological strain known as diabetes distress. The unpredictability of blood glucose levels, combined with constant daily decisions regarding food, medication, exercise, and monitoring, can lead to emotional exhaustion and overwhelm. The burden varies depending on diagnosis timing: children gradually assume responsibilities as they age, while adults diagnosed later must adjust established routines. Additionally, those with existing mental health concerns may face compounded challenges. Endeavor Health's certified diabetes educators address this issue by working collaboratively with patients and care teams to establish realistic goals, reduce anxiety, and build confidence in daily management. The constant barrage of decisions—from calculating carbohydrates to timing insulin doses to planning for emergencies—demonstrates why diabetes creates substantial mental load. Most insurance plans cover diabetes education services, with referrals available through primary care providers or endocrinologists, offering accessible support to help patients transition from burnout to relief.

Mounjaro (tirzepatide), an FDA-approved type 2 diabetes medication manufactured by Eli Lilly, carries a manufacturer list price of $1,112.16 per 28-day supply, though retail cash prices typically range from $1,050 to $1,300 monthly depending on pharmacy overhead and regional factors. The drug is also widely prescribed off-label for weight management, while Zepbound, containing the identical active ingredient tirzepatide, is FDA-approved specifically for long-term weight management in obese or overweight adults with weight-related conditions. Without insurance, patients pay full retail cash prices that vary by pharmacy location and inventory. For insured patients, coverage differs significantly: most commercial insurance plans cover Mounjaro only for type 2 diabetes treatment with out-of-pocket costs ranging from fixed copays to coinsurance percentages, requiring verification through insurer portals or member services. Medicare plans do not cover medications prescribed solely for weight loss, though Medicare Part D and Medicare Advantage typically cover Mounjaro for diabetes treatment. Understanding individual insurance formulary details and prior authorization requirements is essential for determining actual out-of-pocket expenses, as costs vary substantially based on specific plan benefits and coverage criteria.

Compounded semaglutide, a GLP-1 receptor agonist, presents both efficacy and safety considerations for weight management and diabetes treatment. Clinical trials of FDA-approved versions demonstrate common side effects including nausea, vomiting, diarrhea, and constipation, typically mild to moderate and temporary during dose escalation. Management strategies include smaller frequent meals, hydration, reduced fat intake, and dose stabilization when needed. The medication preferentially reduces fat mass over lean mass, prompting the American Diabetes Association to recommend adequate protein intake and resistance training. Critical contraindications include personal or family history of medullary thyroid carcinoma or MEN2 syndrome, based on rodent studies showing thyroid C-cell tumors. Semaglutide carries warnings for pancreatitis, gallbladder complications including gallstones, and potential worsening of existing diabetic retinopathy through rapid blood sugar drops. Pregnancy considerations require discontinuation at least two months before conception due to fetal harm observed in animal studies. The medication is unsuitable for type 1 diabetes and severe gastroparesis. Patients should maintain close communication with prescribers regarding side effects, contraception timing, and monitoring for serious gastrointestinal complications including ileus and intestinal obstruction.

The European Association for the Study of Diabetes has released the first clinical guidelines addressing diabetes distress, recognizing the significant emotional burden experienced by patients managing their condition. Diabetes distress, distinct from depression but often occurring alongside anxiety, affects both type 1 and type 2 diabetes patients and intensifies during diagnosis, treatment changes, complications, or periods of inadequate support. EASD chair Francesco Giorgino emphasized that despite advances in diabetes treatment and technology, the emotional burden has increased for most patients, necessitating routine professional assessment. The groundbreaking guidelines recommend that healthcare professionals assess diabetes distress at least annually using reliable tools, document findings in clinical records, discuss results openly with patients, and develop personalized support or treatment plans accordingly. The Korean Diabetes Association has acknowledged the importance of applying these international standards domestically, highlighting the growing recognition that mental health management is integral to improving overall diabetes outcomes and patient self-management capacity.

As of June 2026, GLP-1 medications for weight loss carry sticker prices of $1,000–$1,350 monthly, but actual patient costs vary dramatically based on insurance coverage, manufacturer savings programs, and direct-pay options. With commercial insurance covering weight loss, Wegovy® and Zepbound® can drop to approximately $25 per fill through manufacturer savings cards. For uninsured patients, manufacturers' direct-to-consumer programs—NovoCare® Pharmacy (Novo Nordisk) and LilyDirect® (Eli Lilly)—offer Wegovy and Zepbound at $199–$449 monthly depending on dose. Medicare excludes weight-loss coverage, though limited pathways exist, while Medicaid coverage varies significantly by state. Recent innovations include the FDA-approved Wegovy® oral pill (December 2025) and Lilly's Foundayo™ (orforglipron, April 2026), creating lower-cost entry points. The landscape has shifted substantially, with both manufacturers now offering steep discounts to cash-paying patients, often providing the most affordable option for those without insurance coverage. Pricing and policies in this category change rapidly, necessitating verification before financial planning.

Researchers from Universitas Padjadjaran in Indonesia investigated the psychological burden experienced by adults managing type 2 diabetes mellitus, focusing on how perceived social support and self-efficacy in diabetes management influence diabetes distress—a diabetes-specific emotional burden linked to long-term disease management challenges. The cross-sectional study enrolled 107 adults with confirmed type 2 diabetes from an internal medicine outpatient clinic in South Sumatra. Participants completed validated Indonesian versions of the Multidimensional Scale of Perceived Social Support, Diabetes Mellitus Self-Efficacy Scale, and Diabetes Distress Scale. The study population averaged 54 years old and was predominantly female (76.6%). Notably, 26.2% of participants experienced moderate-to-high diabetes distress. Using correlation analysis and regression-based path analysis with bootstrap estimation, researchers examined relationships among the three psychosocial variables. These findings illuminate critical connections between social support systems, individual confidence in disease management, and emotional wellbeing in diabetic populations. Understanding these associations has significant implications for developing psychosocial interventions to reduce diabetes-related emotional burden and improve overall patient outcomes in diabetes care management.

GLP-1 medications such as semaglutide, tirzepatide, and orforglipron represent a significant advancement in weight management by mimicking the naturally occurring glucagon-like peptide-1 hormone. These drugs activate GLP-1 receptors in the brain and gut to reduce appetite, increase fullness, and slow stomach emptying. During the critical first month of treatment, patients should anticipate substantial shifts in their relationship with food and hunger, though this adjustment period often involves temporary gastrointestinal discomfort. Appetite changes and GI symptoms typically emerge within days of the initial dose and subsequent dose increases, generally subsiding within a week as the body adapts. Clinicians typically employ a gradual dosing strategy, starting with low starter doses and increasing incrementally over months to minimize side effects. Rather than focusing on rapid weight loss, the first month serves as an adaptation period for learning individual medication responses. To optimize this phase, patients should prioritize protein, fiber, and water intake while consuming smaller, frequent meals lower in fat and sugar. Healthcare providers emphasize that building supportive habits during month one establishes the foundation for sustained long-term weight management success.

A 2026 systematic review and meta-analysis published in Diabetes Research and Clinical Practice examined whether psychotherapy can improve glycemic control in type 2 diabetes patients. The comprehensive analysis of 52 studies evaluated the effects of psychotherapy-based interventions on A1C levels, body weight, and BMI. Results demonstrated that psychotherapy was associated with statistically significant A1C reductions, with the most notable improvement at three months showing a mean difference of -0.53 percentage points. Weight benefits emerged later, with mean reductions of 3.58 kg observed at 12 months. The research suggests psychotherapy does not directly lower glucose like medication but instead works by improving diabetes self-management behaviors, diet adherence, and medication compliance. This findings underscore the importance of treating type 2 diabetes as both a metabolic and behavioral condition, addressing psychological factors including stress, depression, anxiety, and diabetes distress that impede daily management tasks. The results support an integrated care approach combining psychological support with traditional medical interventions, potentially enhancing patient outcomes and overall diabetes management effectiveness.

A systematic review and meta-analysis published in the Journal of Diabetes & Metabolic Disorders examined the prevalence of anxiety and depressive symptoms among adults with type 2 diabetes. Researchers conducted a comprehensive literature review to synthesize data across multiple studies, employing meta-analytical techniques to calculate pooled prevalence estimates. The analysis reveals substantial comorbidity between type 2 diabetes and mental health disorders, with significant proportions of diabetic patients experiencing concurrent anxiety and depression. These findings underscore the importance of integrated mental health screening and treatment within diabetes care protocols. The research highlights that psychological complications frequently accompany metabolic disease management, yet often remain underdiagnosed and undertreated in clinical settings. Understanding the true prevalence of these psychiatric symptoms among diabetic populations enables healthcare providers to develop more comprehensive intervention strategies addressing both metabolic and psychological well-being. This meta-analysis contributes critical epidemiological insights for improving clinical practice standards and patient outcomes in diabetes management through holistic, psychologically-informed care approaches.

# Professional Summary This research, published in Scientific Reports, investigates the psychological well-being of type 2 diabetes patients by examining associated factors that influence their mental health outcomes. Conducted by Mohammad Esmaeelzadeh, Mobin Soleimanian Asl, Amirhossein Boostani, and Simin Sharafi, the study addresses the significant mental health burden experienced by individuals managing this chronic condition. Type 2 diabetes affects millions globally, and while extensive research focuses on glycemic control and physical complications, psychological well-being remains an understudied yet critical component of patient care. This investigation identifies key factors that either support or impede mental health in this population, providing valuable insights for healthcare providers developing comprehensive diabetes management strategies. Understanding these psychological dimensions is essential for improving overall patient outcomes and quality of life, as mental health significantly influences treatment adherence, self-management behaviors, and disease progression. The findings contribute to a more holistic understanding of type 2 diabetes care, emphasizing the need for integrated approaches that address both physical and psychological health dimensions in clinical practice and patient support programs.

People with type 1 diabetes face elevated risks of developing depression, anxiety, diabetes distress, burnout, and eating disorders such as diabulimia, yet these mental health challenges often remain invisible because individuals manage their condition while appearing outwardly functional. This comprehensive guide, written by Julia Flaherty and published in October 2026, addresses the unique psychological burden of living with type 1 diabetes and emphasizes that acknowledging mental health struggles represents strength rather than weakness. The article highlights that type 1 diabetes permeates every aspect of life—mental, physical, emotional, financial, and social—with its relentless 24/7 demands leaving patients without respite. Understanding specific terminology for diabetes-related mental health conditions enables individuals to communicate more effectively with healthcare providers and access appropriate support. Loved ones can identify when intervention is needed by recognizing warning signs including social withdrawal, mood changes, and neglected disease management. The guide underscores that support resources are available globally, with crisis helplines including the 988 number in the United States, demonstrating that individuals need not face these challenges alone and that seeking help is fundamentally an act of strength.

The realization of a truly autonomous and unobtrusive artificial pancreas has long been hindered by the bulky, rigid mechanical drives of commercial insulin pumps and the physically separated glucose sensing unit. In this study, we bridge this engineering gap using an ultra-compact, wireless theranostic platform that synergizes a 9-ANB-functionalized optical microneedle sensor with a structurally novel electrochemical micropump. By engineering a unique semi-dry sandwich electrode that uses highly porous nickel foam to clamp a localized NaOH-saturated fabric, the system achieves highly efficient electrolytic actuation via predictable gas expansion. This structural paradigm shift enables arbitrary internal layout customization, shrinking the integrated device to overall dimensions of approximately 2 cm in diameter and thickness. Furthermore, the synergistic integration of the actuation module with the optically responsive microneedle array establishes a highly robust closed-loop theranostic cycle. By continuously translating glucose-dependent fluorescence variations into precise dosing commands via a smartphone interface, the platform achieves highly predictable, microliter-scale intervention.

The European Association for the Study of Diabetes has published its first evidence-based clinical practice guideline addressing the assessment and management of diabetes distress in adults with type 1 and type 2 diabetes, published in Diabetologia. This guideline formally recognizes that emotional burden management is integral to diabetes care. The guidance includes eight Good Practice Statements recommending that healthcare professionals routinely assess diabetes distress using validated tools during every consultation, monitor at least annually, and maintain open documentation and discussion with patients. When distress is identified, practitioners should develop collaborative management plans and provide tailored follow-up support while building competency in psychological interventions. For management, evidence supports psychological and psychoeducational interventions for both diabetes types. Notably, continuous glucose monitoring and automated insulin delivery systems are recommended specifically for type 1 diabetes patients to reduce distress, though advanced technologies lack evidence for type 2 diabetes applications. This comprehensive guideline represents an important shift toward person-centered diabetes care that acknowledges and systematically addresses the psychological dimensions of living with diabetes.

Mounjaro (tirzepatide), a once-weekly injectable medication, is approved by the FDA for treating type 2 diabetes and reducing cardiovascular risk in high-risk patients. It functions by activating GLP-1 and GIP hormone pathways to enhance insulin release, suppress appetite, and slow gastric emptying. While commercial insurance and Medicare drug plans may cover Mounjaro for type 2 diabetes when listed on their formularies, coverage for weight loss remains uncommon as of 2026, since the medication lacks FDA approval for this indication—though the separate brand Zepbound addresses this use. Insurance coverage often involves prior authorization, step therapy requirements, and documentation of diabetes diagnosis or prior medication trials. Out-of-pocket costs can be substantial without coverage, though manufacturer savings programs and evolving Medicare policies help offset expenses. Patients should contact their insurers directly to confirm whether Mounjaro appears on their formulary and which conditions qualify for reimbursement, as coverage policies vary significantly across plans and continue to evolve.

Continuous glucose monitoring (CGM) patches can cause skin reactions, but determining the cause requires examining three key factors: the reaction's location, onset timing, and symptoms. Redness confined to the overpatch shape that appears within an hour typically indicates friction or moisture irritation, which is easily remedied. Conversely, sharp itching or redness directly under the sensor housing that develops over hours or days suggests an allergic response to the sensor's factory adhesive, requiring different interventions. Irritant reactions emerge quickly due to direct skin damage, while allergic responses develop slowly as the immune system builds sensitization over repeated exposures. Popular CGM devices including Dexcom G6, G7, and ONE+, FreeStyle Libre 2 and 3, Medtronic Guardian, and Omnipod each contain factory-installed adhesive, distinct from separately applied overpatch products. Understanding whether the overpatch or sensor adhesive triggers the reaction is crucial, since switching overpatch brands cannot resolve sensor adhesive sensitivity. Distinguishing between irritant contact dermatitis and allergic contact dermatitis enables targeted solutions and informed decisions about device compatibility and skin preparation strategies.

Mounjaro (tirzepatide), an FDA-approved diabetes medication, is increasingly prescribed off-label for weight management due to demonstrated substantial weight loss in clinical trials. Its pharmaceutical counterpart, Zepbound, contains the same active ingredient and is FDA-approved specifically for long-term weight management in adults with obesity or weight-related conditions. The manufacturer list price for Mounjaro is $1,112.16 per 28-day supply, though retail cash prices typically range from $1,050 to $1,300 monthly depending on pharmacy overhead costs, regional adjustments, and profit margins. Eli Lilly sets identical pricing across all six available dosage strengths. For uninsured patients, the full retail cash price applies at point of purchase. Coverage varies significantly for insured patients based on their specific insurance plans. Most commercial insurance plans cover Mounjaro exclusively when prescribed for type 2 diabetes, with out-of-pocket costs ranging from fixed copays to percentage coinsurance. Medicare plans do not cover medications prescribed solely for weight loss, though Medicare Part D and Medicare Advantage may cover Mounjaro when prescribed for diabetes management. Patients should verify their specific coverage through their insurer's online portal or member services.